Shares of Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) were up 1% on Thursday . The company traded as high as $2.22 and last traded at $2.08. 48,024 shares were traded during mid-day trading, an increase of 38% from the average session volume of 34,754 shares. The stock had previously closed at $2.06.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, August 19th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Analysis on MENS
Jyong Biotech Stock Performance
About Jyong Biotech
Jyong Biotech Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing botanical drug products. The company’s research is centered on plant-derived therapies for urological conditions, including disorders affecting the prostate and urinary system.
Its product development activities have primarily targeted benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms, as well as other prostate-related conditions.
Recommended Stories
- Five stocks we like better than Jyong Biotech
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
